Literature DB >> 17638888

Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis.

Kari D Loomis1, Songyun Zhu, Kyungsil Yoon, Peter F Johnson, Robert C Smart.   

Abstract

CCAAT/enhancer binding protein alpha (C/EBPalpha) is a basic leucine zipper transcription factor that inhibits cell cycle progression and regulates differentiation in various cell types. C/EBPalpha is inactivated by mutation in acute myeloid leukemia (AML) and is considered a human tumor suppressor in AML. Although C/EBPalpha mutations have not been observed in malignancies other than AML, greatly diminished expression of C/EBPalpha occurs in numerous human epithelial cancers including lung, liver, endometrial, skin, and breast, suggesting a possible tumor suppressor function. However, direct evidence for C/EBPalpha as an epithelial tumor suppressor is lacking due to the absence of C/EBPalpha mutations in epithelial tumors and the lethal effect of C/EBPalpha deletion in mouse model systems. To examine the function of C/EBPalpha in epithelial tumor development, an epidermal-specific C/EBPalpha knockout mouse was generated. The epidermal-specific C/EBPalpha knockout mice survived and displayed no detectable abnormalities in epidermal keratinocyte proliferation, differentiation, or apoptosis, showing that C/EBPalpha is dispensable for normal epidermal homeostasis. In spite of this, the epidermal-specific C/EBPalpha knockout mice were highly susceptible to skin tumor development involving oncogenic Ras. These mice displayed decreased tumor latency and striking increases in tumor incidence, multiplicity, growth rate, and the rate of malignant progression. Mice hemizygous for C/EBPalpha displayed an intermediate-enhanced tumor phenotype. Our results suggest that decreased expression of C/EBPalpha contributes to deregulation of tumor cell proliferation. C/EBPalpha had been proposed to block cell cycle progression through inhibition of E2F activity. We observed that C/EBPalpha blocked Ras-induced and epidermal growth factor-induced E2F activity in keratinocytes and also blocked Ras-induced cell transformation and cell cycle progression. Our study shows that C/EBPalpha is dispensable for epidermal homeostasis and provides genetic evidence that C/EBPalpha is a suppressor of epithelial tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638888      PMCID: PMC3773581          DOI: 10.1158/0008-5472.CAN-07-0139

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis.

Authors:  E Sterneck; S Zhu; A Ramirez; J L Jorcano; R C Smart
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

2.  E2F3a stimulates proliferation, p53-independent apoptosis and carcinogenesis in a transgenic mouse model.

Authors:  Qiwei X Paulson; Mark J McArthur; David G Johnson
Journal:  Cell Cycle       Date:  2006-01-16       Impact factor: 4.534

3.  Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.

Authors:  Sigal Gery; Sakae Tanosaki; Shikha Bose; Namrata Bose; Jay Vadgama; H Phillip Koeffler
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

4.  Discovery of epigenetically masked tumor suppressor genes in endometrial cancer.

Authors:  Noriyuki Takai; Norihiko Kawamata; Christine S Walsh; Sigal Gery; Julian C Desmond; Sadie Whittaker; Jonathan W Said; Laura M Popoviciu; Peter A Jones; Isao Miyakawa; H Phillip Koeffler
Journal:  Mol Cancer Res       Date:  2005-05       Impact factor: 5.852

5.  E2F/p107 and E2F/p130 complexes are regulated by C/EBPalpha in 3T3-L1 adipocytes.

Authors:  N A Timchenko; M Wilde; P Iakova; J H Albrecht; G J Darlington
Journal:  Nucleic Acids Res       Date:  1999-09-01       Impact factor: 16.971

6.  C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice.

Authors:  N A Timchenko; M Wilde; G J Darlington
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

7.  Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice.

Authors:  Daniela S Bassères; Elena Levantini; Hongbin Ji; Stefano Monti; Shannon Elf; Tajhal Dayaram; Maris Fenyus; Olivier Kocher; Todd Golub; Kwok-kin Wong; Balazs Halmos; Daniel G Tenen
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

Review 8.  Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors.

Authors:  Peter F Johnson
Journal:  J Cell Sci       Date:  2005-06-15       Impact factor: 5.285

9.  Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation.

Authors:  Minsub Shim; Kristina L Powers; Sarah J Ewing; Songyun Zhu; Robert C Smart
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

10.  C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes.

Authors:  Kyungsil Yoon; Robert C Smart
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

View more
  25 in total

1.  Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes.

Authors:  Katrin Zaragoza; Valérie Bégay; Anja Schuetz; Udo Heinemann; Achim Leutz
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

2.  C/EBPα expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPα confers susceptibility to UVB-induced skin squamous cell carcinomas.

Authors:  Elizabeth A Thompson; Songyun Zhu; Jonathan R Hall; John S House; Rakesh Ranjan; Jeanne A Burr; Yu-Ying He; David M Owens; Robert C Smart
Journal:  J Invest Dermatol       Date:  2011-02-24       Impact factor: 8.551

Review 3.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.

Authors:  A R Lourenço; P J Coffer
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 4.  Epidermal barriers.

Authors:  Ken Natsuga
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 5.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer.

Authors:  Steffen Koschmieder; Balazs Halmos; Elena Levantini; Daniel G Tenen
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

6.  C/EBPalpha redirects androgen receptor signaling through a unique bimodal interaction.

Authors:  J Zhang; M Gonit; M D Salazar; A Shatnawi; L Shemshedini; R Trumbly; M Ratnam
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

7.  C/EBPalpha and C/EBPbeta are required for Sebocyte differentiation and stratified squamous differentiation in adult mouse skin.

Authors:  John S House; Songyun Zhu; Rakesh Ranjan; Keith Linder; Robert C Smart
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

8.  Gene expression profiling identifies lobe-specific and common disruptions of multiple gene networks in testosterone-supported, 17beta-estradiol- or diethylstilbestrol-induced prostate dysplasia in Noble rats.

Authors:  Neville N C Tam; Carol Ying-Ying Szeto; Maureen A Sartor; Mario Medvedovic; Shuk-Mei Ho
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

9.  Expression and sub-cellular localization of the CCAAT/enhancer binding protein alpha in relation to postnatal development and malignancy of the prostate.

Authors:  Juan Zhang; John Erby Wilkinson; Mesfin Gonit; Rick Keck; Steven Selman; Manohar Ratnam
Journal:  Prostate       Date:  2008-08-01       Impact factor: 4.104

10.  C/EBPalpha expression is partially regulated by C/EBPbeta in response to DNA damage and C/EBPalpha-deficient fibroblasts display an impaired G1 checkpoint.

Authors:  R Ranjan; E A Thompson; K Yoon; R C Smart
Journal:  Oncogene       Date:  2009-07-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.